Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

ams.

-- In its alliance with GlaxoSmithKline (GSK), Pharmacopeia reported that

it received a $500 thousand milestone payment for identification of a

compound for advancement into lead optimization six months ahead of the

original schedule. The compound is being evaluated as a potential

treatment for inflammatory pain. Pharmacopeia has already received $10

million from GSK for completion of early discovery activities and is

entitled to receive an additional $5 million payment upon the

completion of additional early discovery activities. Pharmacopeia is

also entitled to success-based milestone payments totaling up to $83

million per program for any drug development program pursued through

the multi-program alliance and up to double-digit royalties on the

sales of any product commercialized by GSK from the alliance.

Subsequent to the end of the third quarter:

Pharmacopeia announced that it has licensed a Phase 1 selective androgen receptor modulator (SARM) program from BMS, including lead and back-up compounds. Pharmacopeia plans to develop the lead compound from this program, PS178990, as a potential novel treatment for muscle wasting associated with a number of serious chronic and acute medical conditions such as surgical and severe burn recovery, end-stage renal disease and cancer- and AIDS-related cachexia. The SARM program has a broad portfolio of pending patent applications that, if granted, would provide intellectual property coverage to the SARM program through at least 2023. PS178990 has been well characterized by BMS both in pre-clinical studies and in a Phase 1 single ascending dose study. The company plans to conduct several Phase 1 studies in 2008, including a multiple ascending dose study of PS178990, to obtain additional safety and tolerability data before entering Phase 2.

In consideration for the SARM program license, Pharmacopei
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015  IntelliQuit™, the world,s first smartphone breathalyzer for smokers, was selected to present as ... New York City on Wednesday April 22.  ... ... ... Thirty percent (30%) of all cardiovascular disease is caused ...
(Date:4/21/2015)... ST. LOUIS , April 21, 2015 ... as a 5.4 percent decrease in utilization helped offset ... according to new data released today by Express Scripts ... Express Scripts Workers, Compensation Drug Trend Report discusses the ... opioid use among injured workers. Opioid ...
(Date:4/21/2015)... April 21, 2015  Navitas has launched Aviator, a ... range of offerings for life sciences clients. Aviator supports ... platform enabling seamless flow of data across all applications ... launch, Navitas worked closely with Oracle to provide Argus, ... CTMS in the Cloud. ...
Breaking Medicine Technology:IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 2IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 2Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 3Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 4
... June 21 Gentris Corporation ( www.gentris.com ), ... that Rick Williams has joined the organization ... Board of Directors.  In his role as CEO of ... continues to provide biotechnology and pharmaceutical sponsors with the ...
... 21 Thomson Reuters announced today that it has launched ... the way biotechnology, pharmaceutical and academic organizations find partnering opportunities around ... , ... with drugs in development. It enables authorized users to share essential ...
Cached Medicine Technology:Gentris Corporation Names New Chief Executive Officer 2Gentris Corporation Names New Chief Executive Officer 3Gentris Corporation Names New Chief Executive Officer 4Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 2Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 3
(Date:4/21/2015)... Chicago, IL (PRWEB) April 21, 2015 ... surgery provider in India for their ongoing commitment to ... Hyderabad strives to provide patients with the best ... to the skin, hair and body. , Executives at ... believes in the philosophy of — nothing about you, ...
(Date:4/21/2015)... Lewisville, TX (PRWEB) April 21, 2015 ... (NYSE:ADPT) announced today it is opening its first freestanding ... located in Chandler, Arizona and will be licensed under ... of the Dignity Health and Adeptus Health joint venture. ... Chandler Regional and Mercy Gilbert Medical Centers said the ...
(Date:4/21/2015)... Information is the best weapon in the fight ... patients and their families with knowledge about living with cancer ... is the Answer" and new website . , In ... patients from diagnosis through treatment and even death. The goal, ... treatment, at home and in the examination room. , “Cancer ...
(Date:4/21/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining ... SUVs. , SUVs are large vehicles that fare well ... and a smaller regular car shows that passengers from the ... SUV safer in crashes, but these large vehicles may be ... , It is now possible to find low cost car ...
(Date:4/21/2015)... QuickMedical, a veteran-owned leader in the ... Schiller America's line of Ambulatory and ... Vital Signs Monitors, among many other items. ... leader in the development and production of cardio-pulmonary ... cooperation with the world's leading physicians and specialists ...
Breaking Medicine News(10 mins):Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Auto Insurance Quotes For SUVs Are Available Online 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3
... world-leading publisher of scientific, technical, and medical information products ... January 2009, the internationally respected Journal of Pain ... be the official journal of the American Academy of ... will continue to serve as the official journal ...
... in Laser and Endoscopic Surgery , , ... Schaeffer, endoscopic reconstructive surgeon and leading nasal expert, has retained ... cosmetic practice. , , ... face, neck, sinuses and skull base, Dr. Schaeffer is credited ...
... 17 Cadence Pharmaceuticals, Inc.,(Nasdaq: CADX ... 304, a,Phase III clinical trial of Acetavance(TM), the ... acute pain following,abdominal laparoscopic surgery. Study 304 ... reduction in summed pain intensity,differences from baseline over ...
... NEW YORK, Dec. 17 Forest Laboratories, Inc. (NYSE: ... Chief Executive Officer exercised stock options for 600,000 shares which ... their 10-year term. Mr. Solomon indicated his intent to ... option exercise, net of those shares withheld by the Company ...
... is linked to hepatitis B, researchers say , , ... increased overall survival in Asian-Pacific patients with advanced liver ... included 226 patients in China, South Korea and Taiwan. ... 400 milligrams of sorafenib (Nexavar) twice a day in ...
... Internet,s fastest-growing job site, predicts the job sectors most likely to ... ... McLean, VA (PRWEB) December 17, 2008 -- Jobfox, the ... trends to watch in 2009. The list includes the job ...
Cached Medicine News:Health News:Elsevier announces new partnership between the Journal of Pain and Symptom Management and the AAHPM 2Health News:Rubenstein Public Relations Retained To Provide Publicity for Foremost Nasal and Cosmetic Surgeon 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 3Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 4Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 5Health News:Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares 2Health News:Drug Helps Asians Battling Liver Cancer 2Health News:The Obama Effect: New Job Trends to Watch in 2009 2Health News:The Obama Effect: New Job Trends to Watch in 2009 3
... The Fundus 20mm is a ... Lens. The Fundus 20mm provides ... increased 20mm contact element. The ... the contact element sits under ...
... The Volk Area Centralis® is excellent ... neovascularization and changes from macular degeneration, ... proliferative diabetic retinopathy and other retinal ... laser treatment of these conditions providing ...
... delivers the widest field of view ... .5x image magnification provides simultaneous visualization of ... providing a greater margin of safety during ... the ideal lens for visualization and treatment ...
... it the "Super 90". Volk's SuperField® has ... diagnosis for today's discriminating practitioner. Its ideal ... make it perfect as the primary high ... SuperField has been specifically designed for increased ...
Medicine Products: